Eli Lilly executive on crucial tirzepatide data: "It is a very exciting time"
![The US pharmaceutical company Eli Lilly is Novo Nordisk's greatest competitor on the diabetes market.](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12495915.ece/ALTERNATES/schema-16_9/20200917-222409-4-1920x1080we%2520(1).jpg)
Before New Year's, the bar will be raised for how well a diabetes drug can perform when Eli Lilly displays the first phase III results from the future hope tirzepatide.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Astrazeneca's covid antibody drug heads into advanced trials
For subscribers
Lundbeck plans to succeed with migraine drug – Teva failed
For subscribers